200 related articles for article (PubMed ID: 2425448)
1. Specific fibrinolytic properties of different molecular forms of pro-urokinase from a monkey kidney cell culture.
Rijken DC; Binnema DJ; Los P
Thromb Res; 1986 Jun; 42(6):761-8. PubMed ID: 2425448
[TBL] [Abstract][Full Text] [Related]
2. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
3. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
Declerck PJ; Lijnen HR; Verstreken M; Moreau H; Collen D
Blood; 1990 May; 75(9):1794-800. PubMed ID: 1691934
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
Gurewich V; Pannell R
Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
[TBL] [Abstract][Full Text] [Related]
6. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.
Gurewich V; Pannell R; Louie S; Kelley P; Suddith RL; Greenlee R
J Clin Invest; 1984 Jun; 73(6):1731-9. PubMed ID: 6725557
[TBL] [Abstract][Full Text] [Related]
7. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
Lijnen HR; De Wreede K; Demarsin E; Collen D
Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
[TBL] [Abstract][Full Text] [Related]
8. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
9. Thrombolytic properties of an inactive proenzyme form of human urokinase secreted from human kidney cells.
Kasai S; Arimura H; Nishida M; Suyama T
Cell Struct Funct; 1985 Jun; 10(2):151-9. PubMed ID: 3924420
[TBL] [Abstract][Full Text] [Related]
10. Characterization and fibrin-binding properties of different molecular forms of pro-urokinase from a monkey kidney cell culture.
Wijngaards G; Rijken DC; van Wezel AL; Groeneveld E; van der Velden CA
Thromb Res; 1986 Jun; 42(6):749-60. PubMed ID: 3088754
[TBL] [Abstract][Full Text] [Related]
11. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.
Pannell R; Gurewich V
Blood; 1986 May; 67(5):1215-23. PubMed ID: 3083889
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
Gurewich V; Pannell R; Broeze RJ; Mao J
J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
[TBL] [Abstract][Full Text] [Related]
13. Activation of plasminogen by pro-urokinase. I. Mechanism.
Lijnen HR; Zamarron C; Blaber M; Winkler ME; Collen D
J Biol Chem; 1986 Jan; 261(3):1253-8. PubMed ID: 2935528
[TBL] [Abstract][Full Text] [Related]
14. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.
Zamarron C; Lijnen HR; Van Hoef B; Collen D
Thromb Haemost; 1984 Aug; 52(1):19-23. PubMed ID: 6495259
[TBL] [Abstract][Full Text] [Related]
15. Effects of pro-urokinase and urokinase on the fibrinolytic system in man.
Trübestein G; Popov S; Wolf H; Welzel D
Haemostasis; 1987; 17(4):238-44. PubMed ID: 2442078
[TBL] [Abstract][Full Text] [Related]
16. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
Samama M; Nguyen G; Desnoyers P; Lourenco DM; Fretault J; Horellou MH; Conard J; Szwarcer E; Verdy E; Vahanian A
Fundam Clin Pharmacol; 1988; 2(6):509-23. PubMed ID: 3149257
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
Gurewich V; Pannell R
Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
[TBL] [Abstract][Full Text] [Related]
18. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
Keijer J; Linders M; van Zonneveld AJ; Ehrlich HJ; de Boer JP; Pannekoek H
Blood; 1991 Jul; 78(2):401-9. PubMed ID: 1712649
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Holmes WE; Collen D
J Biol Chem; 1988 Apr; 263(12):5594-8. PubMed ID: 2965704
[TBL] [Abstract][Full Text] [Related]
20. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.
Cassels R; Fears R; Smith RA
Biochem J; 1987 Oct; 247(2):395-400. PubMed ID: 3122725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
